Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 291

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 12
Chunk 291
---
130   61,409 Change in fixed deposits placed with original maturities more than three months  (78,835)  (1,411,626)Purchase of plant and equipment  (226,989)  (149,398)Proceeds from disposal of investments in equity securities  1,068,777   26,146 Proceeds from settlement of supplier contract dispute  79,851   - Net cash generated from/(used in) investing activities  418,202   (1,794,202)

 F-8Table of Contents

BIONEXUS GENE LAB CORP.CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023(Currency expressed in United States Dollars (“US$”))(CONT’D)(Audited) 

Cash flows from financing activities:      Advances from directors  3,975   13,199 Share-based compensation        141,000   511,740 Shares subscriptions  -   5,750,000 Net cash generated from financing activities  144,975   6,274,939          Foreign currency translation adjustment  40,339   (259,679)NET CHANGE IN CASH AND CASH EQUIVALENTS  (1,630,744)  2,398,846 CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR  4,517,710   2,118,864          CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR $2,886,966  $4,517,710          CASH AND CASH EQUIVALENTS INFORMATION:        Fixed deposits placed with financial institutions with original maturities of three months or less $1,303,487  $1,893,745 Cash at bank  1,583,479   2,623,965 Cash and cash equivalents, end of financial year  2,886,966   4,517,710          Supplementary cash flow information:        Interest paid $(9,351) $(8,877)Income tax refunded  -   312 Income tax paid  (40,380)